含有皮质类固醇的可注射透明质酸水凝胶的制备及其性能。

IF 4.3 3区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutical Sciences Pub Date : 2025-04-08 DOI:10.1016/j.ejps.2025.107096

Jia Meng , Wei Wang , Jiayan Wang , Ming Xu

{"title":"含有皮质类固醇的可注射透明质酸水凝胶的制备及其性能。","authors":"Jia Meng , Wei Wang , Jiayan Wang , Ming Xu","doi":"10.1016/j.ejps.2025.107096","DOIUrl":null,"url":null,"abstract":"<div><div>Chronic rhinosinusitis (CRS), a common chronic sinonasal inflammatory disease, frequently requires surgical intervention, yet postoperative bleeding and adhesions remain challenging. While topical hyaluronic acid (HA) and corticosteroids show therapeutic potential, conventional formulations often suffer from rapid drug release. This study developed a pH-responsive HA hydrogel (HA@F127-MF) loaded with mometasone furoate (MF) to address these limitations. Oxidized HA (OHA) and aminated HA (HA-ADH) were synthesized and verified via FTIR and ¹H NMR. The hydrogel demonstrated exceptional swelling capacity, achieving ∼1500 % equilibrium swelling ratio in PBS within 8 h. Rheological tests revealed rapid gelation, self-healing properties, and favorable viscoelasticity, while SEM confirmed its stable 3D microporous structure. Sustained MF release (79.4 % over 14 days) was achieved with pH-dependent kinetics. In vitro cytotoxicity assays using human nasal epithelial cells (HNEPCs) indicated excellent biocompatibility. APTT and PT tests suggested enhanced hemostatic effects via the intrinsic coagulation pathway. These findings position HA@F127-MF hydrogel as a promising dual-functional platform for CRS postoperative care, combining sustained anti-inflammatory drug delivery with hemorrhage control. However, further in vivo validation and clinical trials are warranted to confirm its efficacy and safety for translational applications. This dynamic drug-release hydrogel design may enhance clinical outcomes by concurrently addressing postoperative bleeding and chronic inflammation.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"211 ","pages":"Article 107096"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fabrication and properties of an injectable hyaluronic acid hydrogel loaded with corticosteroid\",\"authors\":\"Jia Meng , Wei Wang , Jiayan Wang , Ming Xu\",\"doi\":\"10.1016/j.ejps.2025.107096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Chronic rhinosinusitis (CRS), a common chronic sinonasal inflammatory disease, frequently requires surgical intervention, yet postoperative bleeding and adhesions remain challenging. While topical hyaluronic acid (HA) and corticosteroids show therapeutic potential, conventional formulations often suffer from rapid drug release. This study developed a pH-responsive HA hydrogel (HA@F127-MF) loaded with mometasone furoate (MF) to address these limitations. Oxidized HA (OHA) and aminated HA (HA-ADH) were synthesized and verified via FTIR and ¹H NMR. The hydrogel demonstrated exceptional swelling capacity, achieving ∼1500 % equilibrium swelling ratio in PBS within 8 h. Rheological tests revealed rapid gelation, self-healing properties, and favorable viscoelasticity, while SEM confirmed its stable 3D microporous structure. Sustained MF release (79.4 % over 14 days) was achieved with pH-dependent kinetics. In vitro cytotoxicity assays using human nasal epithelial cells (HNEPCs) indicated excellent biocompatibility. APTT and PT tests suggested enhanced hemostatic effects via the intrinsic coagulation pathway. These findings position HA@F127-MF hydrogel as a promising dual-functional platform for CRS postoperative care, combining sustained anti-inflammatory drug delivery with hemorrhage control. However, further in vivo validation and clinical trials are warranted to confirm its efficacy and safety for translational applications. This dynamic drug-release hydrogel design may enhance clinical outcomes by concurrently addressing postoperative bleeding and chronic inflammation.</div></div>\",\"PeriodicalId\":12018,\"journal\":{\"name\":\"European Journal of Pharmaceutical Sciences\",\"volume\":\"211 \",\"pages\":\"Article 107096\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0928098725000958\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725000958","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

慢性鼻窦炎（CRS）是一种常见的慢性鼻窦炎症性疾病，经常需要手术干预，但术后出血和粘连仍然具有挑战性。虽然局部透明质酸（HA）和皮质类固醇显示出治疗潜力，但传统配方往往存在药物快速释放的问题。本研究开发了一种负载糠酸莫米松（MF）的ph响应性HA水凝胶（HA@F127-MF）来解决这些限制。合成了氧化羟基磷灰石（OHA）和胺化羟基磷灰石（HA- adh），并通过FTIR和¹H NMR进行了验证。水凝胶表现出优异的膨胀能力，在PBS中8小时内达到~ 1500%的平衡膨胀率。流变学测试显示其快速凝胶化、自愈性能和良好的粘弹性，而扫描电镜证实了其稳定的三维微孔结构。持续的MF释放（79.4%，超过14天）达到ph依赖动力学。用人鼻上皮细胞（HNEPCs）进行的体外细胞毒性实验表明其具有良好的生物相容性。APTT和PT试验提示通过内在凝血途径增强止血作用。这些发现将HA@F127-MF水凝胶定位为一种有前景的双功能平台，用于CRS术后护理，结合持续的抗炎药物输送和出血控制。然而，需要进一步的体内验证和临床试验来证实其转化应用的有效性和安全性。这种动态药物释放水凝胶设计可以同时解决术后出血和慢性炎症，从而提高临床效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Fabrication and properties of an injectable hyaluronic acid hydrogel loaded with corticosteroid

Chronic rhinosinusitis (CRS), a common chronic sinonasal inflammatory disease, frequently requires surgical intervention, yet postoperative bleeding and adhesions remain challenging. While topical hyaluronic acid (HA) and corticosteroids show therapeutic potential, conventional formulations often suffer from rapid drug release. This study developed a pH-responsive HA hydrogel (HA@F127-MF) loaded with mometasone furoate (MF) to address these limitations. Oxidized HA (OHA) and aminated HA (HA-ADH) were synthesized and verified via FTIR and ¹H NMR. The hydrogel demonstrated exceptional swelling capacity, achieving ∼1500 % equilibrium swelling ratio in PBS within 8 h. Rheological tests revealed rapid gelation, self-healing properties, and favorable viscoelasticity, while SEM confirmed its stable 3D microporous structure. Sustained MF release (79.4 % over 14 days) was achieved with pH-dependent kinetics. In vitro cytotoxicity assays using human nasal epithelial cells (HNEPCs) indicated excellent biocompatibility. APTT and PT tests suggested enhanced hemostatic effects via the intrinsic coagulation pathway. These findings position HA@F127-MF hydrogel as a promising dual-functional platform for CRS postoperative care, combining sustained anti-inflammatory drug delivery with hemorrhage control. However, further in vivo validation and clinical trials are warranted to confirm its efficacy and safety for translational applications. This dynamic drug-release hydrogel design may enhance clinical outcomes by concurrently addressing postoperative bleeding and chronic inflammation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Pharmaceutical Sciences 医学-药学

CiteScore

9.60

自引率

2.20%

发文量

248

审稿时长

50 days

期刊介绍： The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.